Fore Bio
Fore Biotherapeutics
Israel · Founded 2011 · $170.0M raised
- Founded
- 2011
- Business Model
- B2B
- Website
- fore.bio
- Total Funding
- $170.0M
- Last Round
- $75.0M Series DMay 2025
- Rounds
- 4
About
Fore Biotherapeutics is a precision oncology company developing cancer therapies guided by proprietary functional genomics. Its lead program, plixorafenib (FORE-8394), is being evaluated in the FORTE Trial for patients with BRAF-altered solid tumors. The company is committed to patient-first, hypothesis-driven science to address difficult-to-treat cancers.
Summary
Fore Bio is a Biotech company based in Israel, founded in 2011. It has raised $170.0M in total across 4 rounds, most recently a $75.0M Series D round in May 2025. Investors include OrbiMed and Medicxi.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
May 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company